About NeoVista, Inc.

Board of Directors

Bill Greene

Biography

Bill Greene is a general partner at MPM Capital, based in the San Francisco office. He joined MPM in 2002 and focuses on biopharmaceutical and medical device investments. Current and prior investments include Alsius, Archus Orthopedics, Barrier Therapeutics (sold to Stiefel Laboratories), CoTherix (sold to Actelion), Endogastric Solutions, Idun Pharmaceuticals (sold to Pfizer), Intercell AG, NeoVista, QuatRx Pharmaceuticals, and Synergia Pharma.

Bill’s experience prior to MPM includes biotechnology drug development, academic research, and the practice of medicine. From 1998 to 2002 he served as a Senior Clinical Scientist and Epidemiologist at Genentech, where his responsibilities in clinical strategy, trial design and management, regulatory interactions, and safety monitoring spanned projects and products in several therapeutic areas.

From 1991 to 1998, Bill was at Yale Medical School, where he trained in internal medicine and diagnostic radiology, taught medicine, and did clinical research. He has been a Robert Wood Johnson Clinical Scholar at Yale (clinical epidemiology), a Howard Hughes Medical Institute Research Scholar at the NIH (neurobiology), and has done research at Massachusetts General Hospital and the University of Padua, Italy. Bill has published widely, taught and practiced medicine, and has managed a private medical practice. He has been awarded the Henry Christian Award for outstanding research from the American Federation of Clinical Research and is a member of the American College of Physicians and the Society for Clinical Epidemiology and Health Care Research.

Bill received his BA from Wesleyan University and his MD from UCSF, where he is currently an Assistant Professor of Medicine.

About MPM Capital: MPM Capital LP is a global investment management firm focused solely on life sciences investing. One of the largest investment management firms dedicated to the life sciences sector, MPM Capital has offices in Boston and San Francisco. MPM's portfolio ranges from start-ups to large-capitalization public companies, with a primary focus on biopharmaceutical and medical device companies with products nearing commercialization, or those companies that already offer product-driven opportunities. The firm manages over $2.4 billion in assets through the MPM BioVentures family of venture capital funds and the MPM BioEquities public market funds. More information on MPM can be found at www.mpmcapital.com.